Cowealth Medical-KY and Medimaging Integrated Solution (MIS) announced on the 20th the formal signing of a strategic cooperation framework agreement aimed at expanding opportunities in China’s smart healthcare market. Cowealth will invest NT$20 million to acquire a 51% equity stake in Medimaging Dongguan through the purchase of existing shares, along with rights for product localization, taking charge of market operations. Ten products from MIS that have already received certification are expected to enter the market starting in April, gradually contributing to business performance.
Joyce Wang, Chairperson of Cowealth Medical Holdings, emphasized that Cowealth excels at identifying high-potential products and has a comprehensive service network. The company plans to further extend its capabilities into the manufacturing sector through resource integration. In addition to this partnership with MIS, Cowealth is collaborating with other partners, including TPV and Mactron, while actively building an industrial supply chain with biotech and electronics companies in Taiwan.
Wang noted that through this strategic alliance with MIS, and leveraging MIS’s strong R&D capabilities alongside Medimaging Dongguan’s manufacturing base, the two companies aim to develop outstanding products and create mutually beneficial synergies.
According to the agreement, Cowealth will combine its expertise in medical channel marketing and operations with MIS’s strengths in innovative medical device development. Together, they will jointly promote product development and market expansion, offering comprehensive smart healthcare solutions. Medimaging Dongguan has already secured certifications for four products: a digital otoscope, digital oral endoscope, optical coherence tomography scanner, and digital fundus camera. Additionally, six products have obtained overseas certifications, including a digital fundus camera, digital anterior segment camera, digital corneal topographer, digital otoscope, digital dermatoscope, and digital oral endoscope. These ten products are set to be introduced first in telemedicine settings, with business performance expected to ramp up in the second half of the year.
Furthermore, Cowealth will acquire a 51% stake in Medimaging Dongguan, a wholly owned subsidiary of MIS, making it a joint venture between the two companies. Cowealth will invest NT$20 million for its majority share and product localization rights, while MIS retains a 49% stake. Moving forward, Cowealth will be responsible for market operations, providing clinical feedback and identifying market opportunities. MIS will focus on product development, licensing patented technologies, and supporting local manufacturing and certification processes.
Cheng, Chu-Ming, Chairman of MIS, stated that the strategic partnership with Cowealth will go beyond product development and sales, deepening the complementary strengths of both companies in the medical field. Both parties aim to leverage their expertise and resources to create more innovative smart healthcare solutions, delivering breakthroughs and added value to the global healthcare market.
Resource: 瞄準中國智慧醫療商機 合富-KY入股晉弘東莞、十品項先試溫
